# Risperidone Augmentation in Patients With Schizophrenia

> **NCT00289861** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 24 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00289861
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289861, "Risperidone Augmentation in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00289861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*